Exact Sciences PT receives Investment Bank Analyst Rating Update
Exact Sciences (EXAS) reported Q3 EPS of ($0.84), $0.23 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $523.1 million versus the consensus estimate...
EU attempting to revive Iran nuclear deal with market staying pessimistic Crude prices could rebound from oversold conditions but stay off 2022 highs Both Iran, US likely looking...
Cathie Wood announced the upcoming closure of the ARK Transparency ETF Despite declines, investors continue to follow Wood’s holdings closely Consider 2 Ark Invest ETFs that...
Biotechnology stocks represent companies that research, develop or market healthcare-related therapies or products. They typically use living organisms, biological systems, or...
Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX, a gene expression tests for breast, prostate, and colon cancers; Oncotype Test, a tissue test delivering tumor profiling to aid therapy selection for patients with advanced, metastatic, refractory, or recurrent cancer; Oncotype DX AR-V7 Nucleus Detect Test, a liquid-based test for advanced stage prostate cancer; Oncomap ExTra, that provides a complete biological picture of certain refractory, rare, or aggressive cancers; and Covid-19 testing services. The company’s pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research; and Hologic, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.
|Average||60.06 (+40.82% Upside)|
|No. of Analysts||17|